Ondine Biomedical Secures First UK NHS Deal with Antimicrobial Photodisinfection Technology
TL;DR
Ondine Biomedical Inc sealed its first commercial deal with an NHS trust, gaining an early advantage in the healthcare market.
The success is attributed to Steriwave's effectiveness in reducing the need for antibiotics, leading to broader NHS adoption and deployment in healthcare facilities.
Ondine Biomedical's Steriwave is making the world a better place by improving healthcare outcomes, reducing antibiotic use, and contributing to antimicrobial resistance efforts.
Ondine Biomedical Inc is expanding its international presence in Canada, UK, and Spain, while also exploring potential in the United States through FDA phase three trials.
Found this article helpful?
Share it with your network and spread the knowledge!
Ondine Biomedical Inc. has achieved a significant milestone with its first commercial agreement in the United Kingdom's National Health Service system. The Canadian antimicrobial photodisinfection specialist has secured adoption of its Steriwave technology by Pontefract and Pinderfields hospitals following a successful quality initiative involving 500 elective hip and knee surgery patients at Pontefract Hospital. This commercial breakthrough represents a validation of the technology's clinical effectiveness and economic benefits within the UK healthcare system.
Matt Ross, Vice President of Sales & Marketing at Ondine Biomedical, emphasized the importance of this achievement, noting that it follows demonstrated positive patient outcomes and favorable health economics. The company is now positioned to develop a comprehensive business case with the York health economics group and Mid Yorkshire healthcare authorities to support broader NHS adoption across the United Kingdom. This strategic approach leverages the successful results from the initial implementation to build a compelling case for wider healthcare system integration.
The UK adoption forms part of Ondine's expanding global commercial presence, with Steriwave technology now deployed in eight new healthcare facilities. This expansion brings the total to 22 facilities across Canada while simultaneously strengthening the company's footprint in both the UK and Spanish markets. The technology's growing acceptance stems from its demonstrated effectiveness in reducing antibiotic requirements, as evidenced in a UK study examining antimicrobial resistance patterns in surgical settings.
Steriwave's alignment with global antimicrobial resistance initiatives represents a crucial aspect of its value proposition. As healthcare systems worldwide grapple with the growing threat of antibiotic-resistant infections, photodisinfection technology offers a non-antibiotic approach to infection prevention. This positions Ondine's technology as particularly relevant in the current healthcare landscape, where reducing antibiotic usage has become a priority for infection control committees and public health authorities globally.
Looking ahead, Ondine Biomedical plans to continue its European market expansion while capitalizing on established success in the Canadian healthcare system. The company is also preparing for potential United States market entry through FDA phase three clinical trials, which would represent another significant milestone in the technology's global adoption. This multi-pronged growth strategy underscores the company's commitment to addressing the critical challenge of healthcare-associated infections through innovative antimicrobial solutions that complement traditional antibiotic approaches.
Curated from News Direct
